This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2014
  • /
  • 12
  • /
  • Jazz Pharma initiates rolling submission to FDA fo...
Drug news

Jazz Pharma initiates rolling submission to FDA for defibrotide for hepatic Veno-Occlusive Disease

Read time: 1 mins
Last updated:14th Dec 2014
Published:14th Dec 2014
Source: Pharmawand

Jazz Pharmaceuticals plc announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States FDA for defibrotide for the treatment of severe hepatic Veno-Occlusive Disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. Defibrotide has been granted Fast Track Designation to treat severe VOD by the FDA.

Jazz Pharmaceuticals has acquired the rights to defibrotide in the U.S. and other markets in North America, South America and Central America. Jazz Pharmaceuticals markets defibrotide in Europe under the name Defitelio (defibrotide). Defitelio is the first and only licensed product in Europe for the treatment of severe hepatic VOD in patients over one month of age undergoing HSCT therapy.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.